India and South Africa recently urged the World Trade Organization to suspend intellectual property protections for COVID-19 vaccines and treatments. The claim is that this would allow developing countries to manufacture “cheap” COVID-19 therapeutics and vaccines, hastening the end to the pandemic—at least, that’s what proponents claim. They’re wrong. Dangerously wrong. Gutting IP protections won’t make COVID-19 medications more readily available but it will set a terrible precedent that will chill future medical innovation.
Patent
- Enablement
- Fee Shifting
- Litigation
- Federal Circuit Invalidates Mobile Device Targeted Ad Claims on Section 101 Cross-Appeal
- Patent Filings Roundup: Microsoft Battles Daedalus Blue; Intel Gears Up for First-to-File Fight; Electric Blanket Boogaloo
- Eleven Million Patents: Milestones in the History of Invention
- Assessing the Damage from Our COVID Technology Giveaway
- PPAC Meeting: Filings Down Less Than Expected Overall, Office Calls on Congress to Release Previously Collected Fees
Recent Posts
- Federal Circuit Invalidates Mobile Device Targeted Ad Claims on Section 101 Cross-Appeal
- Patent Filings Roundup: Microsoft Battles Daedalus Blue; Intel Gears Up for First-to-File Fight; Electric Blanket Boogaloo
- Eleven Million Patents: Milestones in the History of Invention
- Assessing the Damage from Our COVID Technology Giveaway
- PPAC Meeting: Filings Down Less Than Expected Overall, Office Calls on Congress to Release Previously Collected Fees